Business Trip
Business Trip explores the frontiers of brain and mental health through conversations with founders, investors, and researchers at the intersection of neuroscience and technology.
Episodes
66 episodes
How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and what it takes to build these therapies the way large pharma would—culminating in...
Inside Philanthropy’s Role in Mental & Brain Health
Greg speaks with three leaders in mental health philanthropy: Alyson Nieman from Mindful Philanthropy, Sabrina Gracias from Ortus Foundation, and Christen...
Rick Perry on paving the way for Ibogaine in America
Greg interviews Rick Perry, the former Governor of Texas and former U.S. Secretary of Energy and leading advocate for ibogaine, live at the Real Summit.In this episode, we discuss:How...
Brain Shuttles: A New Path Into the Brain with James Gorman of the Wyss Institute
Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a te...
AI and the future of therapy with Luis Voloch of Jimini Health
Greg and Matias interview Luis Voloch, CEO and Co-Founder of Jimini Health, an AI behavioral health company. He previously co-founded and served as CTO of Immunai, where he applied machine learning to immunology and drug discovery. ...
Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka
Matias interviews Rob Malenka.In this episode, we discuss:Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneousThe bottlenecks including weak repli...
Transforming Skin Cells into Neurons to Treat Alzheimer’s with Brendon Boot of Skin2Neuron
Greg and Matias interview Brendon Boot of Skin2Neuron. Brendon is a neurologist at Harvard and Mayo Clinic with prior experience as Medical Director at Biogen overseeing their Phase 1b Alzheimer’s trials.In this episode, we discuss:<...
Mitochondria and the Future of Health with Natalie Yivgi-Ohana of Minovia
Greg and Matias interview Natalie Yivgi-Ohana of Minovia. Natalie is a life science entrepreneur with twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she perf...
.png)
The 4-Hour Sleepers Redefining Human Limits with Ying-Hui Fu of UCSF
Matias and Greg interview Ying-Hui Fu, PhD, is a Professor of Neurology at UCSF and a world leader in the genetics of sleep. Her lab has discovered the first-known genes behind “natural short sleepers”. Her work bridges human genetics and neuro...
What's wrong with US healthcare and how startups can fix it, with Justin Mares
Matias and Greg interview Justin Mares, co-founder of TrueMed and Kettle & Fire on current US healthcare and how startups have the opportunity to change the system.In this episode, we discuss:How the US system profits fr...
Temporal Interference: The Future of Brain Stimulation with Nir Grossman
Matias and Greg interview Dr. Nir Grossman, one of the world’s leading researchers in neurotechnology. Nir is a lecturer in the Department of Brain Sciences at Imperial College London and a founding fellow of the UK Dementia Research Institute....
The State of Autism Part 2 with James Adams of Gut-Brain-Axis Therapeutics Inc.
Greg and Matias interview Dr. James Adams, professor and autism researcher at Arizona State University and President of Gut-Brain-Axis Therapeutics, on groundbreaking research in autism.In this episode, we discuss:The latest ...
The State of Autism Part 1 with Elizabeth Horn of 2m Foundation
Matias interviews Elizabeth Horn, founder of the 2m Foundation, on the current state of autism and what can we do about it.In this episode, we discuss:The rising prevalence of autism and its impact on societyHow 2m F...
Genetic Medicine for Brain Health with Dana Watt of Breakout Ventures
Matias and Greg interview Dana Watt, a Partner at Breakout Ventures, about genetic medicine for brain and mental health.In this episode, we discuss:How genetic therapies work: addressing underlying causes, not just symptoms<...
Transcranial Focused Ultrasound for Mental Health with Jay Sanguinetti of Sanmai
Greg and Matias interview Jay Sanguinetti, founder of Sanmai Technologies, a startup using transcranial focused ultrasound for the treatment of mental health conditions. Jay has a background in academia, having worked at the Univers...
Navigating FDA clinical trials in Neurotech with Tim Marjenin
Greg and Matias interview Tim Marjenin, a regulatory consultant at MCRA with 16 years of experience at the FDA, to discuss the regulatory landscape for neurotechnology devices.Tim provides insights into the FDA approval process for neuro...
Environmental Toxins and Mental Health with Gurdane Bhutani
Greg and Matias interview Gurdane Bhutani, an investor at MBX Ventures, to discuss the impact of environmental toxins on health and the field of exposomics.Gurdane is an expert in environmental health, with a background in Epidemiology a...
FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.Josh is a leading writer covering the intersectio...
Investing in New Frontiers of Mental Health (Live at SXSW)
Software, hardware, and biotechnology are playing an increasingly transformative role in our mental health and wellness. Join us as we discuss what investors look for in these new companies and how they separate what’s real — and what’s near-te...
Comparing Psychedelic Compounds in Therapy (Live Panel at Battery SF)
Matias hosted a panel at The Battery SF with renowned psychedelics experts, Nolan Williams, Allison Feduccia, Matt Baggott.Nolan is a Stanford professor currently researching ibogaine among other areas in psychiatry and radiology, and h...
What Payers Want with Lili Brillstein
Matias interviews Lili Brillstein about how to work collaboratively with healthcare payers (the ones that reimburse for medical expenses).Lili is a pioneer in the field, having previously led one of the largest bundled payment initiativ...
Decoding the Brain with Ed Boyden
Greg and Matias interview Ed Boyden about neuroscience frontiers and its applications to mental health.Ed is a pioneer in understanding the fundamental mechanisms of the brain. He runs a lab at MIT for Synthetic Neurobiology and is a pr...
.jpg)
5-MeO-DMT in mental healthcare with Steve Rio
Greg and Matias interview Steve Rio about 5-MeO-DMT and its potential role in mental healthcare. Steve is a social impact cofounder, transformational coach, and practitioner at the Enfold Institute, one of the most reputable aboveg...
Tom Insel: Startups, AI, Psychedelics, and SSRIs
Tom Insel is an entrepreneur and former director of the US National Institute of Mental Health, the lead US agency supporting mental health research with a $2 billion budget. Since his time at the NIMH, Tom has built mental health technology, f...
Food as Medicine for Mental Health: Drew Ramsey
What if your next antidepressant was a clam or spinach?Greg & Matias invite Dr. Drew Ramsey to explore nutritional psychiatry - a field exploring how the food we eat can be as powerful as medication in treating mental illnesses like ...
